Gilead awards over $22 million to HIV cure researchers

Gilead Sciences announced the 12 new HIV cure research projects it will support through its HIV cure grants program, a fund totaling more than $22 million.

“We know from decades of work addressing the issue of HIV/AIDS that there is no one-size-fits-all solution,” William Lee, PhD, executive vice president of research at Gilead Sciences, said in a release. “Through partnerships with dedicated and results-driven organizations — such as the worthy recipients of our grant funding — our goal is to help in the discovery and development of a safe and effective cure.”

Over the next 3 years, Gilead will provide funding for scientists to complete their studies in curing HIV through varied, developmental research. Leading institutions, groups and non-profits from around the world will conduct projects focusing on translational research, efficacy studies in animal models and community perspectives of HIV cure. Gilead announced the HIV cure grants program February 2016.

“We are excited about the potential of these projects and are looking forward to seeing the results and learnings that emerge from them,” Lee said in the release.

For almost 3 decades, Gilead has pioneered efforts to end the HIV epidemic by developing antiretroviral therapy to treat HIV/AIDS.

Disclosure: Lee is employed by Gilead.